Regeneron Pharmaceuticals
The Senior Medical Director, Clinical Development, Obesity serves as the Scientific and Medical Lead for clinical teams within the Obesity team at Regeneron. This role guides development strategy and regulatory submissions while collaborating with operational leads, discovery teams, and global patient safety. The position focuses on developing innovative clinical strategies and designing robust Phase 2/3 programs to advance medicines for obesity and related comorbidities.
Headquarters
Tarrytown, New York, United States
Company Size
10001+ employees
Founded
1988
Discover how Regeneron (NASDAQ: REGN) harmonizes biology and technology to create life-changing medicines. Join our team and explore clinical trials.
Quadrant Capital Group LLC Purchases 1,564 Shares of Regeneron Pharmaceuticals, Inc. $REGN
4 hours ago
In 2036, Investors Will Regret Not Loading Up on This Multibagger in the Making
6 hours ago
Will Positive Obesity Data and Dupixent Expansion Efforts Change Regeneron Pharmaceuticals' (REGN) Narrative?
1 day ago
Headquarters
San Francisco, CA
Company Size
201-500 employees
Founded
2018
Industry
Technology
Glassdoor Rating
4.2 / 5
Sarah Johnson
Chief Executive Officer
Michael Chen
Chief Technology Officer
Emily Williams
VP of Engineering
David Rodriguez
VP of Product
Jessica Thompson
Chief Financial Officer
Andrew Park
VP of Sales
View leadership team, funding history,
and employee contacts for Regeneron Pharmaceuticals.
Regeneron: Fairly Valued Now After A Stellar Upswing (NASDAQ:REGN)
1 day ago
Associate Obesity Medical Director
State of Indiana
Medical Director (Contract)
Sitero
Clinical Scientist Associate Director, Late Development Obesity
Amgen
U.S. Regulatory Strategy – Obesity and Related Conditions, Senior Manager
Amgen
Director, Global Clinical Physician - Early Clinical Development Oncology
Bristol Myers Squibb
Director, Clinical Science
Celldex Therapeutics